Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival - Wikidata - awgldk - TriplyDB

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

http://www.wikidata.org/entity/Q33831838

about

Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival.Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms.Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study.Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.MMSA-1 expression pattern in multiple myeloma and its clinical significance.

P2860

Q28547742-D0CD7650-34A1-4AF6-9A4D-C96A1F6FC406 Q30488423-F2D16761-2010-4586-8A98-D9E9F64A1315 Q33721123-FDB4849B-6868-4F16-B566-81D9B7379943 Q37148936-79CA1F22-206A-41D9-9C74-2C6E0471F52C Q37457735-FECB25F7-11D6-4FDC-9397-9AE3F988CA11 Q41561479-8547B133-AB8A-43E2-8F01-D705AF1557C4 Q47776224-7AD303E0-B0B4-42BE-B9BF-6BAAAA62B08A Q52907776-51AFA690-3026-455C-A776-B8BBC0356043

P2860

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

http://www.wikidata.org/entity/Q33831838

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Bortezomib and dexamethasone f ...... prognosis on overall survival

@ast

Bortezomib and dexamethasone f ...... prognosis on overall survival

@en

type

label

Bortezomib and dexamethasone f ...... prognosis on overall survival

@ast

Bortezomib and dexamethasone f ...... prognosis on overall survival

@en

prefLabel

Bortezomib and dexamethasone f ...... prognosis on overall survival

@ast

Bortezomib and dexamethasone f ...... prognosis on overall survival

@en

P1433

Q33831838-36B9735C-771B-47EA-A59C-70610D99D646

P1476

Q33831838-7512CD57-AFDE-450A-89D8-6A4C7BB06D96

P2093

Q33831838-01781257-7603-4DB8-82AA-C798B1F95DC4

Q33831838-27C54C44-AAD0-48EC-8005-237877A62B91

Q33831838-3BA0A3C3-C73A-485C-BC1F-8AE4FACB3DF0

Q33831838-4EE2613F-37BA-4211-9932-D1B79D163812

Q33831838-65A945EA-621B-4FB4-96AD-093F61D4B671

Q33831838-799FC3F1-A0F6-4C11-9A17-2C7DECB936C2

Q33831838-86A042E3-1994-40AE-9098-744ED1E16F0D

Q33831838-95E0C1C2-4405-4E65-827D-A66C35A12B5A

Q33831838-9EADB2E3-7AD9-4499-BF11-F83050C259E1

Q33831838-ADB153A5-14A9-4339-84F1-4097F79C96BA

P2860

Q33831838-11F2092E-B2DA-4903-848D-24B5D76DD549

Q33831838-18737B6C-BC81-48FE-B31A-A99950AD8CF9

Q33831838-192BFF32-A187-42B7-AF90-D5A6F4BAC1B8

Q33831838-19ACF202-E26C-4C63-812B-60978F021084

Q33831838-22BDE206-B35A-4FE0-B2DA-3C78916F456E

Q33831838-258CA919-0486-4926-AC32-7D0465B82130

Q33831838-3B5D1942-EBE6-452D-9BB1-938A89C34D9D

Q33831838-5F269449-A579-43E7-A86A-CFFFDD4F2144

Q33831838-6177BAB1-DE73-4698-AB6A-7EB5205C1AB8

Q33831838-74500D73-2D72-45DD-A285-0C9B277DF8CD

P2888

Q33831838-74384372-EDC4-4C6E-A8E2-6F962B768D75

P304

Q33831838-DC50C50A-F22F-4464-9606-620429A3A7FE

P31

Q33831838-E22102A1-98BD-436F-88E2-35561A3A2B2B

P356

Q33831838-67962DEF-8ADF-4243-BD17-B0C435DA5DFE

P407

Q33831838-2745A0B2-4304-4746-81E5-3E1B1E82F38C

P478

Q33831838-52E8B3FF-BE66-4AD6-B7EA-6B07D0ACE80E

P50

Q33831838-CC9D9C23-E5FB-4E82-88BB-8C054937EE18

P577

Q33831838-3EF7BDA1-E962-4B9F-B226-03B972D4316B

P5875

Q33831838-60129033-9BEC-4679-97BE-2346B2E9885F

P6179

Q33831838-3ACD26F8-AEE1-4BB0-A49F-77659385ADC0

Q33831838-737FB9D5-72BC-4104-BAA8-79F42BD6E52A

P698

Q33831838-18A4CAF6-2718-4895-883B-1742BDEB8C45

P921

Q33831838-2EC01C63-A774-41A2-BAB0-E1999E3D4EAF

P932

Q33831838-47C814A5-B6E8-4756-9766-D7BB265B8791

P356

1471-2407-14-462

P1433

P1476

Bortezomib and dexamethasone f ...... prognosis on overall survival

@en

P2093

Akiko Kimura

http://www.w3.org/2001/XMLSchema#string

Fumiaki Miyamae

http://www.w3.org/2001/XMLSchema#string

Hiromasa Niimi

http://www.w3.org/2001/XMLSchema#string

Keita Kameda

http://www.w3.org/2001/XMLSchema#string

Miki Kido

http://www.w3.org/2001/XMLSchema#string

Misao Atsumi

http://www.w3.org/2001/XMLSchema#string

Suzuko Tanaka

http://www.w3.org/2001/XMLSchema#string

Takayoshi Kiba

http://www.w3.org/2001/XMLSchema#string

Takuo Ito

http://www.w3.org/2001/XMLSchema#string

Yoko Sumitani

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Multiple myeloma: review of 869 cases.

International staging system for multiple myeloma.

P2888

1471-2407-14-462

P304

462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-462

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Toshihisa Nakashima

P577

2014-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263290824

http://www.w3.org/2001/XMLSchema#string

P6179

1030924276

http://www.w3.org/2001/XMLSchema#string

1049055661

http://www.w3.org/2001/XMLSchema#string

P698

24952705

http://www.w3.org/2001/XMLSchema#string

P921

P932

4078016

http://www.w3.org/2001/XMLSchema#string